NSE - Delayed Quote INR

NATCO Pharma Limited (NATCOPHARM.NS)

Compare
1,256.65
-44.55
(-3.42%)
At close: January 24 at 3:30:03 PM GMT+5:30

Key Executives

Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in INR.
NameTitlePayExercisedYear Born
Mr. Venkaiah Chowdary Nannapaneni M. Pharm, MS. MD & Chairman -- -- 1945
Mr. Rajeev Nannapaneni CEO & Vice Chairman -- -- 1977
Mr. S. V. V. N. Appa Rao Chief Financial Officer -- -- --
Dr. Donthineni Linga Rao M.D. President of Technical Affairs & Whole Time Director -- -- 1952
Mr. Chekuri Venkat Ramesh C.S. Company Secretary & Compliance Officer -- -- --
Mr. Potluri Sivaramakrishna Prasad Executive VP of Corporate Engineering Services & Whole Time Director -- -- 1958
Dr. Pavan Ganapati Bhat Executive VP of Technical Operations & Director -- -- 1967
Nadella Malleswara Rao VP & Head of Operations -- -- --
N. Sadasiva Rao Executive Vice President of Corporate Affairs, Legal, Secretarial & Estate Management -- -- --
James Rajakumar Vice President of Marketing & Sales - Domestic -- -- --

NATCO Pharma Limited

Natco House
Road No. 2 Banjara Hills
Hyderabad, 500034
India
91 40 2354 7532 https://www.natcopharma.co.in
Sector: 
Healthcare
Full Time Employees: 
4,016

Description

NATCO Pharma Limited, a pharmaceutical company, engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. It offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. The company offers orthopedic products comprising bisphosphonates, which are oral and injectable drugs; and gastroenterology products consisting of novel drugs for chronic hepatitis-B and hepatitis-C, as well as contract manufacturing services. In addition, it provides cardiology and diabetology products for the treatment of hypertension, stable angina, and CHF. Further, the company offers agro chemicals and biological pest management solutions for management of insects, diseases, and weeds across a range of crops. NATCO Pharma Limited was incorporated in 1981 and is headquartered in Hyderabad, India.

Corporate Governance

NATCO Pharma Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

February 12, 2025 at 10:59 AM UTC - February 17, 2025 at 12:00 PM UTC

NATCO Pharma Limited Earnings Date

Recent Events

November 27, 2024 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers